PMID- 30050306
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220318
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 11
DP  - 2018
TI  - Efficacy and safety assessment of apatinib in patients with advanced gastric 
      cancer: a meta-analysis.
PG  - 4149-4158
LID - 10.2147/OTT.S157466 [doi]
AB  - AIM: This meta-analysis was performed to evaluate the efficacy and safety of 
      apatinib in patients with advanced gastric cancer (AGC). METHODS: After 
      evaluating the inclusion and exclusion criteria, the data of eligible randomized 
      clinical trials (RCTs) were extracted. Outcomes including objective response rate 
      (ORR), disease control rate (DCR), and adverse events (AEs) were analyzed in the 
      meta-analysis. RESULTS: Data of 1,069 patients from 13 RCTs were statistically 
      analyzed. Pooled odds ratio (OR) for ORR and DCR was found to be 0.46 (95% 
      confidence interval [CI]: 0.33, 0.64; P<0.00001) and 0.23 (95% CI: 0.15, 0.36; 
      P<0.00001), respectively. Compared with placebo, apatinib showed statistical 
      significance in AEs at any grade, including leucopenia, neutropenia, 
      thrombocytopenia, diarrhea, hypertension, proteinuria, hand-foot syndrome, and 
      fatigue (all P<0.05). CONCLUSION: The results of our meta-analysis revealed that 
      apatinib shows short-term efficacy over no-apatinib regimens or placebo 
      regardless of its use as first- or second-line chemotherapy or for further 
      treatment in patients with AGC accompanied with apparent AEs of any grade.
FAU - Chen, Jianxin
AU  - Chen J
AD  - Department of Medical Oncology, Quzhou People's Hospital, Quzhou, 324000, 
      Zhejiang, People's Republic of China.
FAU - Wang, Junhui
AU  - Wang J
AD  - Department of Radiation Oncology, Quzhou People's Hospital, Quzhou, 324000, 
      Zhejiang, People's Republic of China, wangjunhui7526@163.com.
LA  - eng
PT  - Journal Article
DEP - 20180719
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC6056163
OTO - NOTNLM
OT  - adverse events
OT  - disease control rate
OT  - objective response rate
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/07/28 06:00
MHDA- 2018/07/28 06:01
PMCR- 2018/07/19
CRDT- 2018/07/28 06:00
PHST- 2018/07/28 06:00 [entrez]
PHST- 2018/07/28 06:00 [pubmed]
PHST- 2018/07/28 06:01 [medline]
PHST- 2018/07/19 00:00 [pmc-release]
AID - ott-11-4149 [pii]
AID - 10.2147/OTT.S157466 [doi]
PST - epublish
SO  - Onco Targets Ther. 2018 Jul 19;11:4149-4158. doi: 10.2147/OTT.S157466. 
      eCollection 2018.